OpRegen® for geographic atrophy maintains positive results

Lineage Cell Therapeutics (originally BioTime, Inc.) has announced positive results with its experimental OpRegen® therapy for geographic atrophy (GA), the advanced stage of dry macular degeneration. The company began enrolling and treating U.S.-based patients in 2017 under David S. Boyer, M.D. (Retina-Vitreous Associates Medical Group, Los Angeles) and H. Richard McDonald, M.D., (West Coast Retina [Read More]

Experimental stem cell treatment continues to maintain vision

A procedure reported here in March 2018 has been shown to continue being a safe and effective method for introducing stem cells into the retina. Eye researcher Professor Pete Coffey, who founded the London Project over a decade ago, has confirmed that two study patients have maintained improvements in their vision five years after surgery. [Read More]

Prima System implant has positive results in dry AMD

Pixium Vision reports that follow-up from 18 to 24 months after implantation showed that their PRIMA Bionic Vision System sustainably elicited light perception in all four dry AMD patients with favorable safety profile. Moreover, the second-generation transparent glasses, enabling to combine natural peripheral vision and prosthetic vision, greatly benefited patients and their visual acuity by 3 [Read More]